Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 4
2013 3
2014 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Cardiovascular events and intensity of treatment in polycythemia vera.
Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, Ruggeri M, Rumi E, Scortechini AR, Santini S, Scarano M, Siragusa S, Spadea A, Tieghi A, Angelucci E, Visani G, Vannucchi AM, Barbui T; CYTO-PV Collaborative Group. Marchioli R, et al. N Engl J Med. 2013 Jan 3;368(1):22-33. doi: 10.1056/NEJMoa1208500. Epub 2012 Dec 8. N Engl J Med. 2013. PMID: 23216616 Free article. Clinical Trial.
Stool Xpert MTB/RIF as a possible diagnostic alternative to sputum in Africa: a systematic review and meta-analysis.
Segala FV, Papagni R, Cotugno S, De Vita E, Susini MC, Filippi V, Tulone O, Facci E, Lattanzio R, Marotta C, Manenti F, Bavaro DF, De Iaco G, Putoto G, Veronese N, Barbagallo M, Saracino A, Di Gennaro F. Segala FV, et al. Among authors: susini mc. Front Public Health. 2023 May 24;11:1117709. doi: 10.3389/fpubh.2023.1117709. eCollection 2023. Front Public Health. 2023. PMID: 37293615 Free PMC article.
Mutations and prognosis in primary myelofibrosis.
Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A, Finke C, Score J, Gangat N, Mannarelli C, Ketterling RP, Rotunno G, Knudson RA, Susini MC, Laborde RR, Spolverini A, Pancrazzi A, Pieri L, Manfredini R, Tagliafico E, Zini R, Jones A, Zoi K, Reiter A, Duncombe A, Pietra D, Rumi E, Cervantes F, Barosi G, Cazzola M, Cross NC, Tefferi A. Vannucchi AM, et al. Among authors: susini mc. Leukemia. 2013 Sep;27(9):1861-9. doi: 10.1038/leu.2013.119. Epub 2013 Apr 26. Leukemia. 2013. PMID: 23619563
Risk of second cancers in chronic myeloproliferative neoplasms.
Susini MC, Masala G, Antonioli E, Pieri L, Guglielmelli P, Palli D, Bosi A, Vannucchi AM. Susini MC, et al. Blood. 2012 Apr 19;119(16):3861-2; author reply 3862-3. doi: 10.1182/blood-2011-12-401455. Blood. 2012. PMID: 22517876 Free article. No abstract available.
Impact of different chemotherapy regimens on intestinal mucosal injury assessed with bedside ultrasound: a study in 213 AML patients.
Benedetti E, Traverso G, Pucci G, Morganti R, Bramanti E, Lippolis P, Susini MC, Mazzantini E, Giubbolini R, Mavilia F, Capochiani E, Neri E, Arena C, Cerri F, De Simone L, Valentini K, Stella SM, Ricchiuto V, Bruno B, Galimberti S. Benedetti E, et al. Among authors: susini mc. Front Oncol. 2023 Nov 1;13:1272072. doi: 10.3389/fonc.2023.1272072. eCollection 2023. Front Oncol. 2023. PMID: 38023169 Free PMC article.
The ERCC2 Gln/Gln polymorphism at codon 751 is not associated with leukaemic transformation in primary myelofibrosis.
Susini MC, Guglielmelli P, Spolverini A, Biamonte F, Mannarelli C, Barosi G, Zoi K, Reiter A, Duncombe A, Cervantes F, Cazzola M, Cross N, Vannucchi AM; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) Investigators. Susini MC, et al. Br J Haematol. 2013 Aug;162(3):424-7. doi: 10.1111/bjh.12376. Epub 2013 May 14. Br J Haematol. 2013. PMID: 23672414 Free article. No abstract available.
Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients.
Scappini B, Gianfaldoni G, Caracciolo F, Mannelli F, Biagiotti C, Romani C, Pogliani EM, Simonetti F, Borin L, Fanci R, Cutini I, Longo G, Susini MC, Angelucci E, Bosi A. Scappini B, et al. Among authors: susini mc. Am J Hematol. 2012 Dec;87(12):1047-51. doi: 10.1002/ajh.23308. Epub 2012 Aug 1. Am J Hematol. 2012. PMID: 23151979 Free article. Clinical Trial.
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.
Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martínez-Trillos A, Casetti I, Colomer D, Pieri L, Pratcorona M, Rotunno G, Sant'Antonio E, Bellini M, Cavalloni C, Mannarelli C, Milanesi C, Boveri E, Ferretti V, Astori C, Rosti V, Cervantes F, Barosi G, Vannucchi AM, Cazzola M; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. Rumi E, et al. Blood. 2014 Aug 14;124(7):1062-9. doi: 10.1182/blood-2014-05-578435. Epub 2014 Jul 1. Blood. 2014. PMID: 24986690 Free PMC article.
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.
Guglielmelli P, Barosi G, Rambaldi A, Marchioli R, Masciulli A, Tozzi L, Biamonte F, Bartalucci N, Gattoni E, Lupo ML, Finazzi G, Pancrazzi A, Antonioli E, Susini MC, Pieri L, Malevolti E, Usala E, Occhini U, Grossi A, Caglio S, Paratore S, Bosi A, Barbui T, Vannucchi AM; AIRC-Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators. Guglielmelli P, et al. Among authors: susini mc. Blood. 2011 Aug 25;118(8):2069-76. doi: 10.1182/blood-2011-01-330563. Epub 2011 Jul 1. Blood. 2011. PMID: 21725052 Free PMC article. Clinical Trial.
11 results